« Return to News | Drug Sponsors

PhaseBio raises additional $23M in Series B financing

Thursday, June 7, 2012 12:05 PM

PhaseBio Pharmaceuticals, a Malvern, Penn.-based, privately-held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, has raised a total of $48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs.

In December 2009, PhaseBio raised $25 million in a Series B financing led by New Enterprise Associates, with participation by OSI Investment Holdings (now Astellas Venture Management) and previous investors Johnson & Johnson Development, Hatteras Venture Partners and Fletcher Spaght Ventures. These investors have now provided an additional $23 million.

The funding will support PhaseBio's phase IIb clinical testing of Glymera for the treatment of type 2 diabetes; a phase I clinical study of Vasomera in patients with stage 1 and 2 essential hypertension and additional preclinical work to support further clinical development of Vasomera for the treatment of acute and chronic heart failure and pulmonary hypertension; and to complete a phase I/IIa clinical study of Insumera, a fully native mature insulin fused to ELP, for type 2 diabetes.

"This additional investment with participation by all of our investors reflects their confidence in the PhaseBio product development programs, our versatile ELP technology platform and the extraordinary progress we have made in advancing our pipeline," said Christopher Prior, Ph.D., CEO of PhaseBio. "This provides us great flexibility in continuing to grow the value of PhaseBio.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.